Protective efficacy and immunogenicity of Escherichia coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis

Medical Microbiology and Immunology

Volumn 194, Issue 4, 2005, Pages 211-217

  Kumar, Varinder ^a   Ganguly, N K ^b   Joshi, Kusum ^b   Mittal, Rahul ^a   Harjai, Kusum ^a   Chhibber, Sanjay ^a   Sharma, Saroj ^a  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; K13 ANTIGEN; K13 ANTIGEN DIPHTHERIA TOXOID CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CONJUGATION; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIPHTHERIA TOXOID; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; IMMUNIZATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; PYELONEPHRITIS; SPLEEN; VACCINES, CONJUGATE;

EID: 23844467723     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-005-0241-x     Document Type: Article

References (43)

1. Williams DH, Schaeffer AJ (2004) Current concepts in urinary tract infections. Minerva Urol Nefrol 56(1):15-31
2. Raksha R, Srinivasa H, Macaden RS (2003) Occurrence and characterization of uropathogenic Escherichia coli in urinary tract infections. Indian J Med Microbiol 21(2):102-107
3. Vogel T, Veerault, R, Gordeau M (2004) Antibiotic treatment for uncomplicated urinary tract infections in the elderly: A comparison of 3-day and 7-day courses. CMAJ 170:469-473
4. Weintraub A (2003) Immunology of bacterial polysaccharide antigens. Carbohydr Res 338(23):2539-2547
5. Kaijser B, Larsson P, Olling S (1978) Protection against ascending Escherichia coli pyelonephritis in rats and significance of local immunity. Infect Immun 20:78-81
6. Kaijser B, Larsson P, Nimmich W, Soderstrom I (1983) Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis. Prog Allergy 30:275-289
7. Stevans P, Young LS, Alam S (1983) Correlation of E. coli K-1 bacteremia and capsular polysaccharide antigenemia in acute and chronic infection. Diagn Microbiol Infect Dis 1(3):185-192
8. Hekker TA, Groeneveld AB, Simoons-Smit AM, de Man P, Connell H, MacLaren DM (2000) Role of bacterial virulence factors and host factors in the outcome of Escherichia coli bacteraemia. Eur J Clin Microbiol Infect Dis 19(4):312-316
9. Burns SM, Hull SI (1999) Loss of resistance to ingestion and phagocytic killing by O(-) and K(-) mutants of a uropathogenic Escherichia coli O75:K5 strain. Infect Immun 67(8):3757-3762
10. Taylor CM, Roberts IS (2005) Capsular polysaccharides and their role in virulence. Contrib Microbiol 12:55-66
11. Palazzi DL, Rench MA, Edwards MS, Baker CJ (2004) Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 190(3):558-564
12. Hu Y, Test ST (2004) Functional differences in IgG anti-polysaccharide antibodies elicited by immunization of mice with C3d versus ovalbumin conjugates of pneumococcal serotype 14 capsular polysaccharide. Vaccine 23(1):21-28
13. Sharma S, Harjai K, Mittal R (1991) Enhanced siderophore production and mouse kidney pathogenicity by urine grown Escherichia coli. J Med Microbiol 35:325-329
14. Sharma S, Kaur R, Yadav V, Harjai K, Joshi K (2004) Contribution of Exotoxin A of Pseudomonas aeruginosa in acute and chronic experimental renal infection. Jpn J Infect Dis 57:119-120
15. Mittal R, Chhibber S, Sharma S, Harjai K (2004) Macrophage inflammatory protein-2, neutrophil recruitment and bacterial persistence in an experimental mouse model of urinary tract infection. Microbes Infect 6(14):1326-1332
16. Mural RJ, Adams MD, Myers EW, Smith HQ, Miklos GL, Wides R, Halporn A (2002) A comparison of whole genome shotgun derived mouse chromosome 16 and the human genome. Science 296(5573):1661-1671
17. Jann K (1985) Isolation and characterization of capsular polysaccharides (K-antigens) from E. coli. In: Sussman M (ed) In the virulence of E. coli. Academic Press, New York pp 375-379
18. Kabat, EA, Mayer M (1961) Carbohydrate estimation. In experimental immunochemistry. Charles C. Thomas, publisher, Springfield III 531
19. Technical Bulletin (1988) E-Toxalate (Limulus Ameboyte Lysate) for detection and semiquantitation of endotoxin. Tech. Bull no 10 Sigma
20. Lowry OH (1951) Protein measurement with the Folin-phenol reagent. J Biol Chem 193:265-275
21. Burton K (1956) Diphenylamino method for DNA estimation. Biochem J 62:315-322
22. Munro P, Fleck A (1966) The determination of nucleic acids. Methods Biochem Anal 14:113-176
23. Schneerson R, Robbins JB, Parke JC, Wang Z, Schifman G, Karpas A, Shiloach J (1986) Quantitative and qualitative analysis of serum antibodies elicited in adults by H. influenzae type and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 52:519-528
24. Garg UC, Ganguly NK, Sharma S, Chakravati RN, Bhatnagar RK (1987) Quantitative histopathological method for evaluation of experimental ascending pyelonephritis. Med Sci Res 15:367-368
25. Nichol AD, Bonventre PF (1985) Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: T lymphocytes mediated immunosuppression. Infect Immun 50:169-174
26. Devi SJ N, Robbins JB, Schneerson R (1991) Antibodies to poly (238)-α-N-acetylneuraminic acid and poly(239)-α-N- acetylneuraminicacid are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci USA 88:7175-7179
27. Granoff DM, Harris SL (2004) Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 23(6):490-497
28. Melegaro A, Edmunds WJ (2004) The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 19(4):365-375
29. Rahn A, Beis K, Naismith JH, Whitfield C (2003) A novel outer membrane protein, Wzi, is involved in surface assembly of the Escherichia coli K30 group 1 capsule. J Bacteriol 185(19):5882-5890
30. Beis K, Collins RF, Ford RC, Kamis AB, Whitfield C, Naismith JH (2004) Three-dimensional structure of Wza, the protein required for translocation of group 1 capsular polysaccharide across the outer membrane of Escherichia coli. J Biol Chem 279(27):28227-28232
31. Lockhart S (2003) Conjugate vaccines. Expert Rev Vaccines 2(5):633-648
32. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL. (2004) Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 189(6):1103-12
33. Baraldo K, Mori E, Bartoloni A, Petracca R, Giannozzi A, Norelli F, Rappuoli R, Grandi G, Del Giudice G. (2004) N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. Infect Immun 72(8):4884-4887
34. Chhibber S, Bhardwaj SB (2004) Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen. J Med Microbiol 53:705-709
35. Dagan R, Kayhty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, Eskola J (2004) Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J 23(2):91-98
36. Devi SJN, Zollinger WD, Snoy PJ, Tai JY, Costantini P, Norelli F, Rappuoli R, Frasch CE (1997) Preclinical evaluation of Group B Neisseria meningitides and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile Rhesus monkeys. Infect Immun 65:1045-1052
37. Maitta RW, Datta K, Lees A, Belouski SS, Liise-anne P (2004) Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun 72:196-208
38. Jansen WT, Snippe H (2004) Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian J Med Res 119(Suppl):7-12
39. Kurnick JT, McCluskey RT, Bhan AK, Wright KA, Wilkinson R, Rubin RH. (1988) Escherichia coli-specific T lymphocytes in experimental pyelonephritis. J Immunol 141(9):3220-3226
40. Miller T (1984) Pyelonephritis: the role of cell-mediated immunity defined in a congenitally athymic rat. Kidney Int 26(6):816-822
41. Miller TE, Marshall E, Nelson J (1983) Infection-induced immunosuppression in pyelonephritis: characteristics of the suppressor cell(s). Kidney Int 24(3):313-322
42. Ahlstedt S, Hagberg M, Jodal U, Marild S (1983) Cell mediated immune parameters in children with pyelonephritis caused by Escherichia coli. Prog Allergy 33:289-297
43. Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, Rodriguez A, Baly A, Herrera L, Izquierdo M, Villar A, Valdes Y, Cosme K, Deler ML, Montane M, Garcia E, Ramos A, Aguilar A, Medina E, Torano G, Sosa I, Hernandez I, Martinez R, Muzachio A, Carmenates A, Costa L, Cardoso F, Campa C, Diaz M, Roy R (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305(5683):522-525